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Corrigendum
Serum levels of IL-6 and TNF-a correlate with clinicopathological
features and patient survival in patients with prostate cancer
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Correction to: British Journal of Cancer (2004) 90, 2312–2316. doi: 10.1038/sj.bjc.6601814
Due to an error, the second author’s name was omitted from the
above paper. The correct author listing is shown below:
V Michalaki, M Odontiadis, K Syrigos, P Charles and J Waxman
Also, in the same paper, part of the labelling in Figures 1 and 2 is
incorrect. The correct figures are reproduced below:
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Figure 1 Disease-specific survival in patients with localised prostate
cancer, stratified into groups above or below the cutoff IL-6 level of
2.1pgml
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Figure 2 Disease-specific survival in patients with localised prostate
cancer, stratified into groups above or below the cutoff TNF-a level of
1.9pgml
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